Evotec Names 20-Year Life Sciences Executive Dr. Ingrid Müller as COO to Lead Horizon Initiative
Evotec has appointed Dr. Ingrid Müller as Chief Operating Officer effective May 1, 2026; she brings over 20 years of international leadership across operations, strategy, supply, procurement and R&D integration. She will oversee global operations and drive execution of the Horizon initiative, targeting improvements in quality, productivity, scalability, delivery and cost control.
1. Appointment Details
Evotec has appointed Dr. Ingrid Müller as Chief Operating Officer effective May 1, 2026. In her new role on the Management Board, she will oversee global operations and lead execution of the company’s Horizon initiative to enhance quality, productivity, scalability, delivery and cost efficiency.
2. Professional Background
Dr. Müller brings over 20 years of leadership in the life sciences sector, including roles as Vice President of Portfolio Strategy & Execution at CureVac and senior positions at Sanofi and Fresenius Kabi. Her track record includes strengthening supply resilience, implementing make-or-buy strategies, expanding margins and delivering annual savings and cash-flow improvements.
3. Expected Impact
The appointment underscores Evotec’s focus on operational excellence as it advances its integrated drug discovery and development platforms. Müller’s expertise in cross-functional execution and transformation is expected to accelerate Evotec’s growth transformation and partner delivery objectives.